Interest in immunosuppression withdrawal among liver transplant and autoimmune hepatitis patients

Eden Sharabi, Allison Carroll, Peter Cummings, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Immunosuppression withdrawal (ISW) is considered in liver transplant recipients (LTRs) and autoimmune hepatitis patients (AIHPs). Immunosuppressive therapy (IST) can be burdensome both financially and due to its side effect profile, making ISW an important intervention to consider. Data on patient interest in ISW would be helpful to providers in ISW decision-making. We conducted independent single-center surveys of LTR and AIHP attitudes on IST and withdrawal interest. Of 325 LTRs screened, 120 completed the survey (50% female, mean age 58 ± 14 years, mean time since transplant 8 ± 10.5 years and 79.5% Caucasian). Of 100 AIHPs screened, 45 completed the survey (77.8% female, mean age 54 ± 2 and 82.2% Caucasian). A higher percentage of AIHPs expressed concern with their IST and were interested in ISW compared with LTRs. However, over a third of LTRs were interested in ISW, particularly those with knowledge of this potential intervention. LTRs who discussed ISW with a physician were more likely to desire withdrawal (p = 0.02; OR = 2.781 (95% CI = 1.125, 6.872)). As patient interest in ISW is of growing interest, investigators should continue to assess patient-reported desires and outcomes and pursue strategies to achieve immunological tolerance.

Original languageEnglish (US)
JournalGastroenterology Insights
Issue number2
StatePublished - Apr 1 2021


  • Autoimmune
  • Decision-making
  • Hepatitis
  • Immunosuppression
  • Liver transplantation
  • Patient-reported outcome measures

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Interest in immunosuppression withdrawal among liver transplant and autoimmune hepatitis patients'. Together they form a unique fingerprint.

Cite this